Use of 1-alpha-hydroxyvitamin d5 and related compounds as prophylactic or therapeutic agents for sars-cov-2 (covid-19 virus) and related infections
OwnerRichard J. Pariza, Robert M. Moriartyinventors
Life of this patent
Estimating the term…
Abstract
The use of 1-alpha-hydroxyvitamin D5 or related compounds as prophylactic or therapeutic agents for SARS-CoV-2 (Covid-19 virus) and related infections. The compounds may be administered orally, by inhalation, nasal spray, eye drops, or by injection. The compounds may be administered to persons who are unwilling, unable or adverse to be vaccinated. The compounds also may be administered to immunocompromised persons for whom vaccination may not provide adequate protection from infection.
Claims11
A method for treating a patient who is Covid-19 positive, the method comprising administering to the patient a pharmaceutically effective amount of 1-alpha-hydroxyvitamin D5 or related compounds.
A method for preventing Covid-19 in a Covid-19 negative person or a person of unknown Covis-19 status, the method comprising administering to the person a pharmaceutically effective amount of 1-alpha-hydroxyvitamin D5 or related compounds as a preventative prophylactic.
Dependencies are inferred from the claim text.